

William J Jagust

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4529969/publications.pdf>

Version: 2024-02-01

348
papers

60,578
citations

1701

104
h-index

1113

231
g-index

374
all docs

374
docs citations

374
times ranked

34494
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantification of amyloid beta and tau PET without a structural MRI. <i>Alzheimer's and Dementia</i> , 2023, 19, 444-455.	0.4	7
2	Elevated Dopamine Synthesis as a Mechanism of Cognitive Resilience in Aging. <i>Cerebral Cortex</i> , 2022, 32, 2762-2772.	1.6	12
3	Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease. <i>Brain</i> , 2022, 145, 713-728.	3.7	43
4	Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 824-857.	0.4	56
5	Abnormal tau in amyloid PET negative individuals. <i>Neurobiology of Aging</i> , 2022, 109, 125-134.	1.5	22
6	Sequential pathway inference for multimodal neuroimaging analysis. <i>Stat</i> , 2022, 11, e433.	0.3	1
7	Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2022, 18, 1370-1382.	0.4	17
8	Associations among locus coeruleus catecholamines, tau pathology, and memory in aging. <i>Neuropsychopharmacology</i> , 2022, 47, 1106-1113.	2.8	27
9	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	4.5	97
10	Visit-to-Visit Blood Pressure Variability and Longitudinal Tau Accumulation in Older Adults. <i>Hypertension</i> , 2022, 79, 629-637.	1.3	14
11	Dissection of the polygenic architecture of neuronal A β production using a large sample of individual iPSC lines derived from Alzheimer's disease patients. <i>Nature Aging</i> , 2022, 2, 125-139.	5.3	7
12	Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer's disease. <i>Nature Communications</i> , 2022, 13, 1495.	5.8	11
13	Rates of A β -amyloid deposition indicate widespread simultaneous accumulation throughout the brain. <i>Neurobiology of Aging</i> , 2022, 115, 1-11.	1.5	4
14	A robust and interpretable machine learning approach using multimodal biological data to predict future pathological tau accumulation. <i>Nature Communications</i> , 2022, 13, 1887.	5.8	16
15	Distinct Factors Drive the Spatiotemporal Progression of Tau Pathology in Older Adults. <i>Journal of Neuroscience</i> , 2022, 42, 1352-1361.	1.7	7
16	Longitudinal Trajectories of Memory Performance in Patients with Early-Stage Breast Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-9.	0.6	0
17	Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 592.	4.5	29
18	Autosomal dominant and sporadic late onset Alzheimer's disease share a common in vivo pathophysiology. <i>Brain</i> , 2022, 145, 3594-3607.	3.7	20

#	ARTICLE	IF	CITATIONS
19	Metacognition, cortical thickness, and tauopathy in aging. <i>Neurobiology of Aging</i> , 2022, 118, 44-54.	1.5	3
20	Association of <i>APOE4</i> and Clinical Variability in Alzheimer Disease With the Pattern of Tau- and Amyloid-PET. <i>Neurology</i> , 2021, 96, e650-e661.	1.5	73
21	Distinct effects of beta-amyloid and tau on cortical thickness in cognitively healthy older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, 1085-1096.	0.4	34
22	Longitudinal Cognitive and Biomarker Measurements Support a Unidirectional Pathway in Alzheimer's Disease Pathophysiology. <i>Biological Psychiatry</i> , 2021, 89, 786-794.	0.7	48
23	Diagnostic Accuracy of Amyloid versus ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography in Autopsy-Confirmed Dementia. <i>Annals of Neurology</i> , 2021, 89, 389-401.	2.8	34
24	Regional Tau Effects on Prospective Cognitive Change in Cognitively Normal Older Adults. <i>Journal of Neuroscience</i> , 2021, 41, 366-375.	1.7	29
25	Spatial Relationships between Molecular Pathology and Neurodegeneration in the Alzheimer's Disease Continuum. <i>Cerebral Cortex</i> , 2021, 31, 1-14.	1.6	34
26	Integrating events in the disintegration of Alzheimer's disease. <i>Brain</i> , 2021, 144, 11-14.	3.7	1
27	Detection of β -amyloid positivity in Alzheimer's Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers. <i>Brain Communications</i> , 2021, 3, fcab008.	1.5	51
28	Reduced Repetition Suppression in Aging is Driven by Tau-Related Hyperactivity in Medial Temporal Lobe. <i>Journal of Neuroscience</i> , 2021, 41, 3917-3931.	1.7	16
29	Crossed cerebellar diaschisis on ¹⁸ F-FDG PET: Frequency across neurodegenerative syndromes and association with ¹¹ C-PIB and ¹⁸ F-Flortaucipir. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 2329-2343.	2.4	9
30	Youthfulness begins in youth. <i>Nature Aging</i> , 2021, 1, 239-240.	5.3	2
31	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 396.	4.5	146
32	Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 99.	3.0	53
33	Alzheimer's Pathology Is Associated with Dedifferentiation of Intrinsic Functional Memory Networks in Aging. <i>Cerebral Cortex</i> , 2021, 31, 4781-4793.	1.6	24
34	KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimer's disease. <i>Nature Communications</i> , 2021, 12, 3825.	5.8	29
35	The changing definition of Alzheimer's disease. <i>Lancet Neurology</i> , The, 2021, 20, 414-415.	4.9	7
36	Tau and β -Amyloid Burden Predict Actigraphy-Measured and Self-Reported Impairment and Misperception of Human Sleep. <i>Journal of Neuroscience</i> , 2021, 41, 7687-7696.	1.7	17

#	ARTICLE	IF	CITATIONS
37	Multiplex Mass Spectrometry Analysis of Amyloid Proteins in Human Plasma for Alzheimer's Disease Diagnosis. <i>Journal of Proteome Research</i> , 2021, 20, 4106-4112.	1.8	6
38	Evaluation of [¹⁸ F]-JNJ-64326067-AAA tau PET tracer in humans. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 3302-3313.	2.4	15
39	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 961.	4.5	148
40	Accelerated functional brain aging in pre-clinical familial Alzheimer's disease. <i>Nature Communications</i> , 2021, 12, 5346.	5.8	43
41	Hippocampal Connectivity with Retrosplenial Cortex is Linked to Neocortical Tau Accumulation and Memory Function. <i>Journal of Neuroscience</i> , 2021, 41, 8839-8847.	1.7	12
42	Fusiform gyrus phospho-tau is associated with failure of proper name retrieval in aging. <i>Annals of Neurology</i> , 2021, 90, 988-993.	2.8	4
43	Staging tau pathology with tau PET in Alzheimer's disease: a longitudinal study. <i>Translational Psychiatry</i> , 2021, 11, 483.	2.4	23
44	Temporal Dynamics of ¹² I-Amyloid Accumulation in Aging and Alzheimer Disease. <i>Neurology</i> , 2021, 96, e1347-e1357.	1.5	54
45	Head injury is associated with tau deposition on PET in MCI and AD patients. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12230.	1.2	5
46	Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2259-2271.	3.3	10
47	Alzheimer Disease Spectrum. <i>Neurology</i> , 2021, 96, 299-300.	1.5	5
48	Tau Atrophy Variability Reveals Phenotypic Heterogeneity in Alzheimer's Disease. <i>Annals of Neurology</i> , 2021, 90, 751-762.	2.8	19
49	Age, vascular disease, and Alzheimer's disease pathologies in amyloid negative elderly adults. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 174.	3.0	15
50	The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI's updates and global perspectives. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12226.	1.8	23
51	Simultaneous Covariance Inference for Multimodal Integrative Analysis. <i>Journal of the American Statistical Association</i> , 2020, 115, 1279-1291.	1.8	3
52	Spatial patterns of tau deposition are associated with amyloid, ApoE, sex, and cognitive decline in older adults. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2155-2164.	3.3	20
53	Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	353
54	Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration. <i>Molecular Neurodegeneration</i> , 2020, 15, 57.	4.4	33

#	ARTICLE	IF	CITATIONS
55	Association of CSF A β ² , amyloid PET, and cognition in cognitively unimpaired elderly adults. <i>Neurology</i> , 2020, 95, e2075-e2085.	1.5	31
56	Association of vascular brain injury, neurodegeneration, amyloid, and cognitive trajectory. <i>Neurology</i> , 2020, 95, e2622-e2634.	1.5	27
57	Sleep Disturbance Forecasts β ² -Amyloid Accumulation across Subsequent Years. <i>Current Biology</i> , 2020, 30, 4291-4298.e3.	1.8	110
58	Normalization of CSF pTau measurement by A β ²⁴⁰ improves its performance as a biomarker of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 97.	3.0	31
59	Tau spreads through episodic memory networks in the aging brain. <i>Alzheimer's and Dementia</i> , 2020, 16, e037502.	0.4	0
60	Evaluation of a visual interpretation method for tau-PET with ¹⁸ F-flortaucipir. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12133.	1.2	17
61	¹⁸ F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases. <i>Brain</i> , 2020, 143, 3477-3494.	3.7	100
62	Relevance of biomarkers across different neurodegenerative diseases. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 56.	3.0	42
63	Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease. <i>Nature Communications</i> , 2020, 11, 2612.	5.8	283
64	Association Between Common Variants in <i>RBFOX1</i> , an RNA-Binding Protein, and Brain Amyloidosis in Early and Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2020, 77, 1288.	4.5	41
65	Neurophysiological signatures in Alzheimer's disease are distinctly associated with TAU, amyloid- β ² accumulation, and cognitive decline. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	59
66	Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults. <i>Neurology</i> , 2020, 94, e1512-e1524.	1.5	53
67	Longitudinal structural and metabolic changes in frontotemporal dementia. <i>Neurology</i> , 2020, 95, e140-e154.	1.5	39
68	Modelling prognostic trajectories of cognitive decline due to Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2020, 26, 102199.	1.4	48
69	Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LC-MS/MS Reference Method. <i>Clinical Chemistry</i> , 2020, 66, 587-597.	1.5	15
70	Imaging Tau Pathology—The Next Step. <i>JAMA Neurology</i> , 2020, 77, 796.	4.5	6
71	Imaging biomarkers in neurodegeneration: current and future practices. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 49.	3.0	96
72	Conscientiousness is associated with less amyloid deposition in cognitively normal aging.. <i>Psychology and Aging</i> , 2020, 35, 993-999.	1.4	7

#	ARTICLE	IF	CITATIONS
73	Spatially Adaptive Varying Correlation Analysis for Multimodal Neuroimaging Data. IEEE Transactions on Medical Imaging, 2019, 38, 113-123.	5.4	4
74	Tau deposition is associated with functional isolation of the hippocampus in aging. Nature Communications, 2019, 10, 4900.	5.8	67
75	Tau PET and multimodal brain imaging in patients at risk for chronic traumatic encephalopathy. NeuroImage: Clinical, 2019, 24, 102025.	1.4	53
76	What are the threats to successful brain and cognitive aging?. Neurobiology of Aging, 2019, 83, 130-134.	1.5	20
77	“Alzheimer’s disease” is neither “Alzheimer’s clinical syndrome” nor “dementia”. Alzheimer’s and Dementia, 2019, 15, 153-157.	0.4	23
78	18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. Alzheimer’s Research and Therapy, 2019, 11, 13.	3.0	121
79	Sleep as a Potential Biomarker of Tau and β -Amyloid Burden in the Human Brain. Journal of Neuroscience, 2019, 39, 6315-6324.	1.7	160
80	Development of a mnemonic discrimination task using naturalistic stimuli with applications to aging and preclinical Alzheimer’s disease. Learning and Memory, 2019, 26, 219-228.	0.5	17
81	Alzheimer’s pathology targets distinct memory networks in the ageing brain. Brain, 2019, 142, 2492-2509.	3.7	131
82	Tau covariance patterns in Alzheimer’s disease patients match intrinsic connectivity networks in the healthy brain. NeuroImage: Clinical, 2019, 23, 101848.	1.4	73
83	Effect of Off-Target Binding on ¹⁸ F-Flortaucipir Variability in Healthy Controls Across the Life Span. Journal of Nuclear Medicine, 2019, 60, 1444-1451.	2.8	96
84	Dopaminergic Mechanisms Underlying Normal Variation in Trait Anxiety. Journal of Neuroscience, 2019, 39, 2735-2744.	1.7	36
85	Vascular Burden Score Impacts Cognition Independent of Amyloid PET and MRI Measures of Alzheimer’s Disease and Vascular Brain Injury. Journal of Alzheimer’s Disease, 2019, 68, 187-196.	1.2	25
86	Longitudinal tau accumulation and atrophy in aging and alzheimer disease. Annals of Neurology, 2019, 85, 229-240.	2.8	198
87	Multisite study of the relationships between <i>antemortem</i> [¹¹ C]PIB-PET Centiloid values and <i>postmortem</i> measures of Alzheimer’s disease neuropathology. Alzheimer’s and Dementia, 2019, 15, 205-216.	0.4	155
88	Understanding disease progression and improving Alzheimer’s disease clinical trials: Recent highlights from the Alzheimer’s Disease Neuroimaging Initiative. Alzheimer’s and Dementia, 2019, 15, 106-152.	0.4	302
89	Age-related variability in decision-making: Insights from neurochemistry. Cognitive, Affective and Behavioral Neuroscience, 2019, 19, 415-434.	1.0	17
90	Biomarkers for tau pathology. Molecular and Cellular Neurosciences, 2019, 97, 18-33.	1.0	163

#	ARTICLE	IF	CITATIONS
91	Scan-Time Corrections for 80-100-min Standardized Uptake Volume Ratios to Measure the ¹⁸ F-AV-1451 Tracer for Tau Imaging. IEEE Transactions on Medical Imaging, 2019, 38, 697-709.	5.4	4
92	Relationships Between Tau and Glucose Metabolism Reflect Alzheimer's Disease Pathology in Cognitively Normal Older Adults. Cerebral Cortex, 2019, 29, 1997-2009.	1.6	61
93	Cortical tau deposition follows patterns of entorhinal functional connectivity in aging. ELife, 2019, 8, .	2.8	83
94	Spontaneous eye blink rate and dopamine synthesis capacity: preliminary evidence for an absence of positive correlation. European Journal of Neuroscience, 2018, 47, 1081-1086.	1.2	66
95	Following the pathway to Alzheimer's disease. Nature Neuroscience, 2018, 21, 306-308.	7.1	7
96	Subthreshold Amyloid Predicts Tau Deposition in Aging. Journal of Neuroscience, 2018, 38, 4482-4489.	1.7	101
97	Brain morphology, cognition, and β -amyloid in older adults with superior memory performance. Neurobiology of Aging, 2018, 67, 162-170.	1.5	63
98	NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 535-562.	0.4	5,861
99	Metabolic brain networks in aging and preclinical Alzheimer's disease. NeuroImage: Clinical, 2018, 17, 987-999.	1.4	29
100	Associations between [¹⁸ F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology, 2018, 90, e282-e290.	1.5	113
101	Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia. JAMA Neurology, 2018, 75, 342.	4.5	76
102	Prevalence of the apolipoprotein E ϵ 4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.4	58
103	Memory decline accompanies subthreshold amyloid accumulation. Neurology, 2018, 90, e1452-e1460.	1.5	116
104	Increased Striatal Dopamine Synthesis Capacity in Gambling Addiction. Biological Psychiatry, 2018, 83, 1036-1043.	0.7	97
105	Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease. NeuroImage: Clinical, 2018, 17, 452-464.	1.4	126
106	Dopamine Synthesis Capacity is Associated with D2/3 Receptor Binding but Not Dopamine Release. Neuropsychopharmacology, 2018, 43, 1201-1211.	2.8	43
107	Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
108	Associations Between Tau, β -Amyloid, and Cognition in Parkinson Disease. JAMA Neurology, 2018, 75, 227.	4.5	57

#	ARTICLE	IF	CITATIONS
109	Old Brains Come Uncoupled in Sleep: Slow Wave-Spindle Synchrony, Brain Atrophy, and Forgetting. <i>Neuron</i> , 2018, 97, 221-230.e4.	3.8	343
110	Entorhinal Tau Pathology, Episodic Memory Decline, and Neurodegeneration in Aging. <i>Journal of Neuroscience</i> , 2018, 38, 530-543.	1.7	201
111	Head to head comparison of [18F] AV-1451 and [18F] THK5351 for tau imaging in Alzheimer's disease and frontotemporal dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 432-442.	3.3	51
112	F5â€³â€³: RESISTANCE TO AD OVER THE LIFECOURSE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1629.	0.4	0
113	Imaging the evolution and pathophysiology of Alzheimer disease. <i>Nature Reviews Neuroscience</i> , 2018, 19, 687-700.	4.9	372
114	The Influence of Dopamine on Cognitive Flexibility Is Mediated by Functional Connectivity in Young but Not Older Adults. <i>Journal of Cognitive Neuroscience</i> , 2018, 30, 1330-1344.	1.1	27
115	Assessment of Extent and Role of Tau in Subcortical Vascular Cognitive Impairment Using ¹⁸ F-AV1451 Positron Emission Tomography Imaging. <i>JAMA Neurology</i> , 2018, 75, 999.	4.5	85
116	A New Tool for Clinical Neuroscienceâ€”Synaptic Imaging. <i>JAMA Neurology</i> , 2018, 75, 1181.	4.5	5
117	Regional correlations between [11 C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort. <i>NeuroImage: Clinical</i> , 2017, 13, 130-137.	1.4	50
118	Frontotemporal dementia with the V337M <i>MAPT</i> mutation. <i>Neurology</i> , 2017, 88, 758-766.	1.5	76
119	Tau and β -Amyloid Are Associated with Medial Temporal Lobe Structure, Function, and Memory Encoding in Normal Aging. <i>Journal of Neuroscience</i> , 2017, 37, 3192-3201.	1.7	110
120	Amyloid and tau PET demonstrate region-specific associations in normal older people. <i>NeuroImage</i> , 2017, 150, 191-199.	2.1	67
121	Elevated ¹⁸ F-AV-1451 PET tracer uptake detected in incidental imaging findings. <i>Neurology</i> , 2017, 88, 1095-1097.	1.5	38
122	Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. <i>Alzheimer's and Dementia</i> , 2017, 13, e1-e85.	0.4	213
123	Association between tau deposition and antecedent amyloid- β accumulation rates in normal and early symptomatic individuals. <i>Brain</i> , 2017, 140, 1499-1512.	3.7	93
124	Alzheimer Disease Signature Neurodegeneration and <i>APOE</i> Genotype in Mild Cognitive Impairment With Suspected Nonâ€”Alzheimer Disease Pathophysiology. <i>JAMA Neurology</i> , 2017, 74, 650.	4.5	24
125	The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. <i>Alzheimer's and Dementia</i> , 2017, 13, 561-571.	0.4	266
126	The Complexity of Subjective Cognitive Decline. <i>JAMA Neurology</i> , 2017, 74, 1400.	4.5	15

#	ARTICLE	IF	CITATIONS
127	¹⁸ F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study. <i>Annals of Neurology</i> , 2017, 82, 622-634.	2.8	148
128	White Matter Structure in Older Adults Moderates the Benefit of Sleep Spindles on Motor Memory Consolidation. <i>Journal of Neuroscience</i> , 2017, 37, 11675-11687.	1.7	42
129	Earliest accumulation of β -amyloid occurs within the default-mode network and concurrently affects brain connectivity. <i>Nature Communications</i> , 2017, 8, 1214.	5.8	596
130	Subjective cognitive decline and β -amyloid burden predict cognitive change in healthy elderly. <i>Neurology</i> , 2017, 89, 2002-2009.	1.5	53
131	Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease. <i>Brain</i> , 2017, 140, 3286-3300.	3.7	472
132	Considerations and code for partial volume correcting [¹⁸ F]-AV-1451 tau PET data. <i>Data in Brief</i> , 2017, 15, 648-657.	0.5	204
133	Reference Tissue-Based Kinetic Evaluation of ¹⁸ F-AV-1451 for Tau Imaging. <i>Journal of Nuclear Medicine</i> , 2017, 58, 332-338.	2.8	94
134	[F4-04]: NEURAL ACTIVITY REVEALED WITH FMRI IS RELATED TO BETA-AMYLOID AND TAU DEPOSITION IN HEALTHY AGING. <i>Alzheimer's and Dementia</i> , 2017, 13, P1215.	0.4	0
135	Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2017, 11, 281.	1.4	62
136	Hippocampal activation is associated with longitudinal amyloid accumulation and cognitive decline. <i>ELife</i> , 2017, 6, .	2.8	95
137	Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. <i>NeuroImage</i> , 2017, 157, 448-463.	2.1	341
138	Effects of Beta-Amyloid on Resting State Functional Connectivity Within and Between Networks Reflect Known Patterns of Regional Vulnerability. <i>Cerebral Cortex</i> , 2016, 26, bhu259.	1.6	85
139	Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimer's Disease Patients Measured Using [18F] THK-5351. <i>PLoS ONE</i> , 2016, 11, e0158460.	1.1	85
140	A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. <i>Neurology</i> , 2016, 87, 539-547.	1.5	1,216
141	Tract-Specific Correlates of Neuropsychological Deficits in Patients with Subcortical Vascular Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 1125-1135.	1.2	11
142	P1-253: Diagnostic Accuracy of Amyloid- β Versus Fdg-Pet in Autopsy-Confirmed Dementia. <i>Alzheimer's and Dementia</i> , 2016, 12, P506.	0.4	0
143	P2-162: NREM Slow Wave Activity < 1HZ as a Biomarker and Long-Term Predictor of B-Amyloid Burden in Older Adults. , 2016, 12, P676-P677.		0
144	IC-P-055: Centiloid Thresholds for Amyloid Positivity Derived from Autopsy-Proven Cases. , 2016, 12, P45-P46.		0

#	ARTICLE	IF	CITATIONS
145	P1â€295: SNAP: Alzheimer's Disease Plus Overlapping Nonâ€Ad Patterns in The Aging Brain?. Alzheimer's and Dementia, 2016, 12, P533.	0.4	0
146	P2â€285: CENTILOID THRESHOLDS FOR AMYLOID POSITIVITY DERIVED FROM AUTOPSYâ€PROVEN CASES. Alzheimer's and Dementia, 2016, 12, P739.	0.4	0
147	F1-03-03: How ad-Specific are ab and TAU Imaging Biomarkers?. , 2016, 12, P166-P167.		0
148	Impact of lifestyle dimensions on brain pathology and cognition. Neurobiology of Aging, 2016, 40, 164-172.	1.5	23
149	Modulation of impulsivity and reward sensitivity in intertemporal choice by striatal and midbrain dopamine synthesis in healthy adults. Journal of Neurophysiology, 2016, 115, 1146-1156.	0.9	40
150	PET Imaging of Tau Deposition in the Aging Human Brain. Neuron, 2016, 89, 971-982.	3.8	899
151	Accelerating rates of cognitive decline and imaging markers associated with β^2 -amyloid pathology. Neurology, 2016, 86, 1887-1896.	1.5	42
152	Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. JAMA Neurology, 2016, 73, 721.	4.5	235
153	Dynamic relationships between age, amyloid- β^2 deposition, and glucose metabolism link to the regional vulnerability to Alzheimerâ€™s disease. Brain, 2016, 139, 2275-2289.	3.7	75
154	Cortical sources of resting state EEG rhythms are related to brain hypometabolism in subjects with Alzheimer's disease: an EEG-PET study. Neurobiology of Aging, 2016, 48, 122-134.	1.5	53
155	Neuropsychiatric subsyndromes and brain metabolic network dysfunctions in early onset Alzheimer's disease. Human Brain Mapping, 2016, 37, 4234-4247.	1.9	55
156	Association of Serum Docosahexaenoic Acid With Cerebral Amyloidosis. JAMA Neurology, 2016, 73, 1208.	4.5	72
157	Early life sets the stage for aging. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9148-9150.	3.3	14
158	Tau and β^2 -Amyloidâ€The Malignant Duo. JAMA Neurology, 2016, 73, 1049.	4.5	3
159	Aging Affects Dopaminergic Neural Mechanisms of Cognitive Flexibility. Journal of Neuroscience, 2016, 36, 12559-12569.	1.7	116
160	Diagnostic utility of ASLâ€MRI and FDGâ€PET in the behavioral variant of FTD and AD. Annals of Clinical and Translational Neurology, 2016, 3, 740-751.	1.7	42
161	Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer's Disease?. Trends in Neurosciences, 2016, 39, 552-566.	4.2	320
162	Suspected non-Alzheimer disease pathophysiology â€” concept and controversy. Nature Reviews Neurology, 2016, 12, 117-124.	4.9	230

#	ARTICLE	IF	CITATIONS
163	Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18 F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid- β -Positive Subjects in the Alzheimer's Disease Continuum. <i>Neurodegenerative Diseases</i> , 2016, 16, 87-94.	0.8	35
164	Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI. <i>Neurology</i> , 2016, 86, 1377-1385.	1.5	103
165	β -amyloid, hippocampal atrophy and their relation to longitudinal brain change in cognitively normal individuals. <i>Neurobiology of Aging</i> , 2016, 40, 173-180.	1.5	27
166	Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. <i>Brain</i> , 2016, 139, 1551-1567.	3.7	833
167	Is amyloid- β harmful to the brain? Insights from human imaging studies. <i>Brain</i> , 2016, 139, 23-30.	3.7	87
168	Amyloid in dementia associated with familial FTLD: not an innocent bystander. <i>Neurocase</i> , 2016, 22, 76-83.	0.2	12
169	Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. <i>Brain</i> , 2016, 139, 2528-2539.	3.7	58
170	P2-132: Association of cerebral microhemorrhages with amyloid deposition and hyperlipidemia. , 2015, 11, P534-P535.		0
171	IC-01-01: Are low levels of PiB-PET signal clinically significant?. , 2015, 11, P1-P1.		0
172	P3-145: Are low levels of PiB-PET signal clinically significant?. , 2015, 11, P681-P682.		0
173	Alzheimer risk genes modulate the relationship between plasma apoE and cortical PiB binding. <i>Neurology: Genetics</i> , 2015, 1, e22.	0.9	12
174	IC-P-058: Amyloid negativity in clinically diagnosed ADNI Alzheimer's disease and MCI patients. , 2015, 11, P44-P44.		0
175	Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. <i>Annals of Neurology</i> , 2015, 77, 338-342.	2.8	124
176	Improved Power for Characterizing Longitudinal Amyloid- β PET Changes and Evaluating Amyloid-Modifying Treatments with a Cerebral White Matter Reference Region. <i>Journal of Nuclear Medicine</i> , 2015, 56, 560-566.	2.8	122
177	β -amyloid disrupts human NREM slow waves and related hippocampus-dependent memory consolidation. <i>Nature Neuroscience</i> , 2015, 18, 1051-1057.	7.1	411
178	Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease. <i>Human Brain Mapping</i> , 2015, 36, 4421-4437.	1.9	196
179	Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. <i>Brain</i> , 2015, 138, 2020-2033.	3.7	319
180	IC-P-037: Association of cerebral microhemorrhages with amyloid deposition and hyperlipidemia. , 2015, 11, P33-P34.		0

#	ARTICLE	IF	CITATIONS
181	O4-01-06: Tau PET with [18 F]AV1451 in non-alzheimer's disease neurodegenerative syndromes. , 2015, 11, P268-P269.		0
182	Independent information from cerebrospinal fluid amyloid- β^2 and florbetapir imaging in Alzheimer's disease. Brain, 2015, 138, 772-783.	3.7	200
183	Brain structure and function as mediators of the effects of amyloid on memory. Neurology, 2015, 84, 1136-1144.	1.5	44
184	Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures. Neurology, 2015, 84, 729-737.	1.5	36
185	The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. Alzheimer's and Dementia, 2015, 11, 1.	0.4	603
186	The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function. NeuroImage, 2015, 105, 357-368.	2.1	38
187	The EADC&ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity. Alzheimer's and Dementia, 2015, 11, 111-125.	0.4	162
188	2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimer's and Dementia, 2015, 11, e1-120.	0.4	261
189	Genotype status of the dopamine-related catechol-O-methyltransferase (COMT) gene corresponds with desirability of "unhealthy" foods. Appetite, 2015, 92, 74-80.	1.8	14
190	Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimer's and Dementia, 2015, 11, 865-884.	0.4	181
191	The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. Brain, 2015, 138, 2732-2749.	3.7	397
192	The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015. Alzheimer's and Dementia, 2015, 11, 757-771.	0.4	199
193	<i>APOE</i> effect on Alzheimer's disease biomarkers in older adults with significant memory concern. Alzheimer's and Dementia, 2015, 11, 1417-1429.	0.4	157
194	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
195	Prevalence of Amyloid PET Positivity in Dementia Syndromes. JAMA - Journal of the American Medical Association, 2015, 313, 1939.	3.8	501
196	Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β^2 -Amyloid Measures Across the Spectrum of Alzheimer Disease. JAMA Neurology, 2015, 72, 571.	4.5	87
197	Predicting Reduction of Cerebrospinal Fluid β^2 -Amyloid 42 in Cognitively Healthy Controls. JAMA Neurology, 2015, 72, 554.	4.5	42
198	Measurement of Longitudinal β^2 -Amyloid Change with ¹⁸ F-Florbetapir PET and Standardized Uptake Value Ratios. Journal of Nuclear Medicine, 2015, 56, 567-574.	2.8	273

#	ARTICLE	IF	CITATIONS
199	Regional brain hypometabolism is unrelated to regional amyloid plaque burden. <i>Brain</i> , 2015, 138, 3734-3746.	3.7	101
200	Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes. <i>JAMA Neurology</i> , 2015, 72, 1183.	4.5	57
201	The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data. <i>Alzheimer's and Dementia</i> , 2015, 11, 1050-1068.	0.4	98
202	Loss of functional connectivity is greater outside the default mode network in nonfamilial early-onset Alzheimer's disease variants. <i>Neurobiology of Aging</i> , 2015, 36, 2678-2686.	1.5	72
203	GWAS of longitudinal amyloid accumulation on ¹⁸ F-florbetapir PET in Alzheimer's disease implicates microglial activation gene <i>IL1RAP</i> . <i>Brain</i> , 2015, 138, 3076-3088.	3.7	117
204	Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI. <i>Alzheimer Disease and Associated Disorders</i> , 2015, 29, 101-109.	0.6	14
205	IMAGING VASCULAR DISEASE AND AMYLOID IN THE AGING BRAIN: IMPLICATIONS FOR TREATMENT. <i>Journal of prevention of Alzheimer's disease, The</i> , 2015, 2, 1-7.	1.5	25
206	Dorsal Striatal Dopamine, Food Preference and Health Perception in Humans. <i>PLoS ONE</i> , 2014, 9, e96319.	1.1	19
207	Before it is too late: professional responsibilities in late-onset Alzheimer's research and pre-symptomatic prediction. <i>Frontiers in Human Neuroscience</i> , 2014, 8, 921.	1.0	24
208	Is Verbal Episodic Memory in Elderly with Amyloid Deposits Preserved Through Altered Neuronal Function?. <i>Cerebral Cortex</i> , 2014, 24, 2210-2218.	1.6	36
209	Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 266-273.	0.9	47
210	Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 534-543.	1.7	96
211	Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. <i>Acta Neuropathologica Communications</i> , 2014, 2, 26.	2.4	77
212	Associations Between Serum Cholesterol Levels and Cerebral Amyloidosis. <i>JAMA Neurology</i> , 2014, 71, 195.	4.5	201
213	Covarying alterations in A β 2 deposition, glucose metabolism, and gray matter volume in cognitively normal elderly. <i>Human Brain Mapping</i> , 2014, 35, 297-308.	1.9	88
214	Time for tau. <i>Brain</i> , 2014, 137, 1570-1571.	3.7	11
215	Impaired Prefrontal Sleep Spindle Regulation of Hippocampal-Dependent Learning in Older Adults. <i>Cerebral Cortex</i> , 2014, 24, 3301-3309.	1.6	117
216	Vascular risk and A β 2 interact to reduce cortical thickness in AD vulnerable brain regions. <i>Neurology</i> , 2014, 83, 40-47.	1.5	83

#	ARTICLE	IF	CITATIONS
217	Gene-Environment Interactions: Lifetime Cognitive Activity, APOE Genotype, and Beta-Amyloid Burden. <i>Journal of Neuroscience</i> , 2014, 34, 8612-8617.	1.7	107
218	Neural compensation in older people with brain amyloid- β^2 deposition. <i>Nature Neuroscience</i> , 2014, 17, 1316-1318.	7.1	167
219	Association of brain amyloid- β^2 with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment. <i>Brain</i> , 2014, 137, 1550-1561.	3.7	150
220	Association of plasma and cortical amyloid beta is modulated by ϵ APOE ϵ μ 4 status. <i>Alzheimer's and Dementia</i> , 2014, 10, e9-e18.	0.4	43
221	Neuroprotective pathways: lifestyle activity, brain pathology, and cognition in cognitively normal older adults. <i>Neurobiology of Aging</i> , 2014, 35, 1873-1882.	1.5	102
222	Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology. <i>NeuroImage: Clinical</i> , 2014, 4, 508-516.	1.4	59
223	Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia</i> , 2014, 10, S226-35.	0.4	51
224	IC-02-03: EXISTING THRESHOLDS FOR PIB POSITIVITY ARE TOO HIGH. , 2014, 10, P4-P5.		1
225	O1-01-06: COMPARING LIBERAL AND CONSERVATIVE THRESHOLDS FOR AMYLOID PET POSITIVITY IN AUTOPSY-PROVEN CASES. , 2014, 10, P130-P131.		0
226	O3-10-02: LIFETIME COGNITIVE ACTIVITY, APOLIPOPROTEIN E GENOTYPE, AND BRAIN BETA-AMYLOID. , 2014, 10, P228-P228.		1
227	P3-007: LOSS OF FUNCTIONAL CONNECTIVITY IS GREATER OUTSIDE THE DEFAULT MODE NETWORK IN NON-FAMILIAL EARLY-ONSET AD VARIANTS. , 2014, 10, P628-P629.		0
228	Differences in Prefrontal, Limbic, and White Matter Lesion Volumes According to Cognitive Status in Elderly Patients with First-Onset Subsyndromal Depression. <i>PLoS ONE</i> , 2014, 9, e87747.	1.1	10
229	Frontotemporal Network Connectivity during Memory Encoding Is Increased with Aging and Disrupted by Beta-Amyloid. <i>Journal of Neuroscience</i> , 2013, 33, 18425-18437.	1.7	58
230	Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β^2 amyloid. <i>Annals of Neurology</i> , 2013, 74, 826-836.	2.8	320
231	Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. <i>Lancet Neurology</i> , The, 2013, 12, 207-216.	4.9	3,378
232	The Receiver Operational Characteristic for Binary Classification with Multiple Indices and Its Application to the Neuroimaging Study of Alzheimer's Disease. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2013, 10, 173-180.	1.9	20
233	Apolipoprotein E, Neurodegeneration, and Alzheimer Disease. <i>JAMA Neurology</i> , 2013, 70, 299.	4.5	6
234	The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. <i>Alzheimer's and Dementia</i> , 2013, 9, e111-94.	0.4	535

#	ARTICLE	IF	CITATIONS
235	The effect of amyloid $\hat{\tau}^2$ on cognitive decline is modulated by neural integrity in cognitively normal elderly. <i>Alzheimer's and Dementia</i> , 2013, 9, 687.	0.4	59
236	Prefrontal atrophy, disrupted NREM slow waves and impaired hippocampal-dependent memory in aging. <i>Nature Neuroscience</i> , 2013, 16, 357-364.	7.1	434
237	Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. <i>Alzheimer's and Dementia</i> , 2013, 9, 677-686.	0.4	51
238	Alzheimer's Disease Neurodegenerative Biomarkers Are Associated with Decreased Cognitive Function but Not $\hat{\tau}^2$ -Amyloid in Cognitively Normal Older Individuals. <i>Journal of Neuroscience</i> , 2013, 33, 5553-5563.	1.7	133
239	Amyloid- $\hat{\tau}^2$ Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods. <i>Journal of Nuclear Medicine</i> , 2013, 54, 70-77.	2.8	364
240	Dissociable Effects of Alzheimer Disease and White Matter Hyperintensities on Brain Metabolism. <i>JAMA Neurology</i> , 2013, 70, 1039.	4.5	54
241	Vulnerable Neural Systems and the Borderland of Brain Aging and Neurodegeneration. <i>Neuron</i> , 2013, 77, 219-234.	3.8	285
242	Genetic effects on behavior are mediated by neurotransmitters and large-scale neural networks. <i>NeuroImage</i> , 2013, 66, 203-214.	2.1	32
243	Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. <i>Brain</i> , 2013, 136, 844-858.	3.7	280
244	Intrinsic connectivity networks in healthy subjects explain clinical variability in Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 11606-11611.	3.3	105
245	Plasma Acetylcholinesterase Activity Correlates with Intracerebral $\hat{\tau}^2$ -Amyloid Load. <i>Current Alzheimer Research</i> , 2013, 10, 48-56.	0.7	13
246	The Aging Brain and Cognition. <i>JAMA Neurology</i> , 2013, 70, 488.	4.5	113
247	Effect of Cognitive Reserve Markers on Alzheimer Pathologic Progression. <i>Alzheimer Disease and Associated Disorders</i> , 2013, 27, 343-350.	0.6	67
248	Associations Between Alzheimer Disease Biomarkers, Neurodegeneration, and Cognition in Cognitively Normal Older People. <i>JAMA Neurology</i> , 2013, 70, 1512-9.	4.5	139
249	Biomarkers and Brain Connectivity. <i>JAMA Neurology</i> , 2013, 70, 1233-4.	4.5	4
250	Associations between White Matter Hyperintensities and $\hat{\tau}^2$ Amyloid on Integrity of Projection, Association, and Limbic Fiber Tracts Measured with Diffusion Tensor MRI. <i>PLoS ONE</i> , 2013, 8, e65175.	1.1	77
251	The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). <i>Frontiers in Aging Neuroscience</i> , 2013, 5, 11.	1.7	126
252	Prospective study of cognitive function (cog fcn) in women with early-stage breast cancer (BC): Relationship between perceived and measurable cognitive deficits.. <i>Journal of Clinical Oncology</i> , 2013, 31, 6619-6619.	0.8	1

#	ARTICLE	IF	CITATIONS
253	Prospective study of cognitive function (cog fcn) in women with early-stage breast cancer (ESBC): Predictors of cognitive decline.. Journal of Clinical Oncology, 2013, 31, 6620-6620.	0.8	1
254	Prospective study of cognitive function (cog fcn) in women with early-stage breast cancer (ESBC): Predictors of cognitive decline.. Journal of Clinical Oncology, 2013, 31, 104-104.	0.8	3
255	Prospective study of cognitive function (cog fcn) in women with early-stage breast cancer (BC): Relationship between perceived and measurable cognitive deficits.. Journal of Clinical Oncology, 2013, 31, 105-105.	0.8	1
256	Plasma acetylcholinesterase activity correlates with intracerebral β^2 -amyloid load. Current Alzheimer Research, 2013, 10, 48-56.	0.7	24
257	Vascular burden and Alzheimer disease pathologic progression. Neurology, 2012, 79, 1349-1355.	1.5	138
258	Physical Activity and AD-Related Pathologyâ€”Reply. Archives of Neurology, 2012, 69, 940.	4.9	17
259	Association of Lifetime Cognitive Engagement and Low β^2 -Amyloid Deposition. Archives of Neurology, 2012, 69, 623.	4.9	278
260	Using Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta. Advances in Pharmacology, 2012, 64, 27-81.	1.2	78
261	Striatal Dopamine Influences the Default Mode Network to Affect Shifting between Object Features. Journal of Cognitive Neuroscience, 2012, 24, 1960-1970.	1.1	52
262	CSF Biomarker and PIB-PET-Derived Beta-Amyloid Signature Predicts Metabolic, Gray Matter, and Cognitive Changes in Nondemented Subjects. Cerebral Cortex, 2012, 22, 1993-2004.	1.6	92
263	Summary Metrics to Assess Alzheimer Diseaseâ€”Related Hypometabolic Pattern with ¹⁸ F-FDG PET: Head-to-Head Comparison. Journal of Nuclear Medicine, 2012, 53, 592-600.	2.8	79
264	Subjective Cognition and Amyloid Deposition Imaging. Archives of Neurology, 2012, 69, 223.	4.9	261
265	A β Deposition in Aging Is Associated with Increases in Brain Activation during Successful Memory Encoding. Cerebral Cortex, 2012, 22, 1813-1823.	1.6	126
266	Associations Among Vascular Risk Factors, Carotid Atherosclerosis, and Cortical Volume and Thickness in Older Adults. Stroke, 2012, 43, 2865-2870.	1.0	48
267	Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Annals of Neurology, 2012, 72, 578-586.	2.8	559
268	Cardiovascular risk factors, cortisol, and amyloid β^2 deposition in Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2012, 8, 483-489.	0.4	113
269	The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimer's and Dementia, 2012, 8, S1-68.	0.4	432
270	Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. Neurobiology of Aging, 2012, 33, 215-225.	1.5	122

#	ARTICLE	IF	CITATIONS
271	Dopamine and frontostriatal networks in cognitive aging. <i>Neurobiology of Aging</i> , 2012, 33, 623.e15-623.e24.	1.5	65
272	Cerebrovascular disease, beta-amyloid, and cognition in aging. <i>Neurobiology of Aging</i> , 2012, 33, 1006.e25-1006.e36.	1.5	112
273	Coronary risk correlates with cerebral amyloid deposition. <i>Neurobiology of Aging</i> , 2012, 33, 1979-1987.	1.5	66
274	Effects of age and β -amyloid on cognitive changes in normal elderly people. <i>Neurobiology of Aging</i> , 2012, 33, 2746-2755.	1.5	42
275	Apolipoprotein E, Not Fibrillar β -Amyloid, Reduces Cerebral Glucose Metabolism in Normal Aging. <i>Journal of Neuroscience</i> , 2012, 32, 18227-18233.	1.7	146
276	Dopamine Supports Coupling of Attention-Related Networks. <i>Journal of Neuroscience</i> , 2012, 32, 9582-9587.	1.7	118
277	Tracking brain amyloid- β in presymptomatic Alzheimer's disease. <i>Lancet Neurology</i> , The, 2012, 11, 1018-1020.	4.9	3
278	Relative contributions of biomarkers in Alzheimer's disease. <i>Annals of Epidemiology</i> , 2012, 22, 868-875.	0.9	8
279	Not quite PIB-positive, not quite PIB-negative: Slight PIB elevations in elderly normal control subjects are biologically relevant. <i>NeuroImage</i> , 2012, 59, 1152-1160.	2.1	137
280	Brain imaging in the study of Alzheimer's disease. <i>NeuroImage</i> , 2012, 61, 505-516.	2.1	109
281	CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer's pathological cascade. <i>Brain Imaging and Behavior</i> , 2012, 6, 599-609.	1.1	46
282	Amyloid pathway-based candidate gene analysis of [11C]PIB-PET in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. <i>Brain Imaging and Behavior</i> , 2012, 6, 1-15.	1.1	47
283	β Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 209-219.	3.3	55
284	β -Amyloid affects frontal and posterior brain networks in normal aging. <i>NeuroImage</i> , 2011, 54, 1887-1895.	2.1	98
285	Lifespan brain activity, β -amyloid, and Alzheimer's disease. <i>Trends in Cognitive Sciences</i> , 2011, 15, 520-526.	4.0	186
286	Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. <i>Neurobiology of Aging</i> , 2011, 32, 1207-1218.	1.5	611
287	Characterizing Alzheimer's disease using a hypometabolic convergence index. <i>NeuroImage</i> , 2011, 56, 52-60.	2.1	144
288	The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011, 7, 270-279.	0.4	7,498

#	ARTICLE	IF	CITATIONS
289	Factors affecting A β plasma levels and their utility as biomarkers in ADNI. <i>Acta Neuropathologica</i> , 2011, 122, 401-13.	3.9	151
290	Correlations of striatal dopamine synthesis with default network deactivations during working memory in younger adults. <i>Human Brain Mapping</i> , 2011, 32, 947-961.	1.9	50
291	Spatial patterns of brain amyloid- β burden and atrophy rate associations in mild cognitive impairment. <i>Brain</i> , 2011, 134, 1077-1088.	3.7	97
292	Relationships between Beta-Amyloid and Functional Connectivity in Different Components of the Default Mode Network in Aging. <i>Cerebral Cortex</i> , 2011, 21, 2399-2407.	1.6	306
293	Longitudinal Change of Biomarkers in Cognitive Decline. <i>Archives of Neurology</i> , 2011, 68, 1257.	4.9	152
294	Early ¹¹ C-PIB Frames and ¹⁸ F-FDG PET Measures Are Comparable: A Study Validated in a Cohort of AD and FTLN Patients. <i>Journal of Nuclear Medicine</i> , 2011, 52, 173-179.	2.8	72
295	Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. <i>Lancet Neurology</i> , 2010, 9, 119-128.	4.9	3,792
296	Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. <i>Brain</i> , 2010, 133, 512-528.	3.7	242
297	Twelve-month metabolic declines in probable Alzheimer's disease and amnesic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer's Disease Neuroimaging Initiative. <i>NeuroImage</i> , 2010, 51, 654-664.	2.1	145
298	The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. <i>Alzheimer's and Dementia</i> , 2010, 6, 221-229.	0.4	464
299	White matter integrity and cortical metabolic associations in aging and dementia. , 2010, 6, 54-62.		49
300	Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans. <i>Alzheimer's and Dementia</i> , 2010, 6, 239-246.	0.4	402
301	Genes and cognitive aging. <i>Frontiers in Neuroscience</i> , 2009, 3, 161-163.	1.4	5
302	Striatal Dopamine Predicts Outcome-Specific Reversal Learning and Its Sensitivity to Dopaminergic Drug Administration. <i>Journal of Neuroscience</i> , 2009, 29, 1538-1543.	1.7	315
303	Striatal Dopamine and Working Memory. <i>Cerebral Cortex</i> , 2009, 19, 445-454.	1.6	251
304	Amyloid + Activation = Alzheimer's?. <i>Neuron</i> , 2009, 63, 141-143.	3.8	13
305	Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). <i>NeuroImage</i> , 2009, 45, 1107-1116.	2.1	258
306	Cerebral blood flow in ischemic vascular dementia and Alzheimer's disease, measured by arterial spin-labeling magnetic resonance imaging. <i>Alzheimer's and Dementia</i> , 2009, 5, 454-462.	0.4	163

#	ARTICLE	IF	CITATIONS
307	Mapping brain β -amyloid. <i>Current Opinion in Neurology</i> , 2009, 22, 356-361.	1.8	23
308	Neuropathological basis of magnetic resonance images in aging and dementia. <i>Annals of Neurology</i> , 2008, 63, 72-80.	2.8	282
309	β amyloid and glucose metabolism in three variants of primary progressive aphasia. <i>Annals of Neurology</i> , 2008, 64, 388-401.	2.8	434
310	Relationship of Striatal Dopamine Synthesis Capacity to Age and Cognition. <i>Journal of Neuroscience</i> , 2008, 28, 14320-14328.	1.7	87
311	Working Memory Capacity Predicts Dopamine Synthesis Capacity in the Human Striatum. <i>Journal of Neuroscience</i> , 2008, 28, 1208-1212.	1.7	264
312	Cognitive and Anatomic Contributions of Metabolic Decline in Alzheimer Disease and Cerebrovascular Disease. <i>Archives of Neurology</i> , 2008, 65, 650-5.	4.9	41
313	What Can Imaging Reveal about Obesity and the Brain?. <i>Current Alzheimer Research</i> , 2007, 4, 135-139.	0.7	40
314	Profiles of neuropsychological impairment in autopsy-defined Alzheimer's disease and cerebrovascular disease. <i>Brain</i> , 2007, 130, 731-739.	3.7	242
315	Automated template-based PET region of interest analyses in the aging brain. <i>NeuroImage</i> , 2007, 34, 608-617.	2.1	47
316	FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. <i>Brain</i> , 2007, 130, 2616-2635.	3.7	508
317	Positron emission tomography and magnetic resonance imaging in the diagnosis and prediction of dementia. , 2006, 2, 36-42.		53
318	Brain imaging evidence of preclinical Alzheimer's disease in normal aging. <i>Annals of Neurology</i> , 2006, 59, 673-681.	2.8	220
319	Cognitive impact of subcortical vascular and Alzheimer's disease pathology. <i>Annals of Neurology</i> , 2006, 60, 677-687.	2.8	236
320	White Matter Changes Compromise Prefrontal Cortex Function in Healthy Elderly Individuals. <i>Journal of Cognitive Neuroscience</i> , 2006, 18, 418-429.	1.1	195
321	White Matter Changes Compromise Prefrontal Cortex Function in Healthy Elderly Individuals. <i>Journal of Cognitive Neuroscience</i> , 2006, 18, 418-429.	1.1	108
322	Dementia: finding the signals in the noise. <i>Lancet Neurology</i> , The, 2005, 4, 10-11.	4.9	7
323	Central Obesity and the Aging Brain. <i>Archives of Neurology</i> , 2005, 62, 1545-8.	4.9	254
324	Anatomical Mapping of White Matter Hyperintensities (WMH). <i>Stroke</i> , 2005, 36, 50-55.	1.0	459

#	ARTICLE	IF	CITATIONS
325	Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI). , 2005, 1, 55-66.		925
326	White matter lesions are associated with cortical atrophy more than entorhinal and hippocampal atrophy. <i>Neurobiology of Aging</i> , 2005, 26, 553-559.	1.5	104
327	Molecular neuroimaging in Alzheimer's disease. <i>NeuroRx</i> , 2004, 1, 206-212.	6.0	58
328	Correlates of memory function in community-dwelling elderly: The importance of white matter hyperintensities. <i>Journal of the International Neuropsychological Society</i> , 2004, 10, 371-81.	1.2	30
329	Molecular neuroimaging in Alzheimer's disease. <i>Neurotherapeutics</i> , 2004, 1, 206-212.	2.1	0
330	Prevalence of Dementia in Older Latinos: The Influence of Type 2 Diabetes Mellitus, Stroke and Genetic Factors. <i>Journal of the American Geriatrics Society</i> , 2003, 51, 169-177.	1.3	356
331	Brain function and cognition in a community sample of elderly Latinos. <i>Neurology</i> , 2002, 59, 378-383.	1.5	73
332	Positron Emission Tomography in Evaluation of Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2001, 286, 2120.	3.8	803
333	Neuropathologic Substrates of Ischemic Vascular Dementia. <i>Journal of Neuropathology and Experimental Neurology</i> , 2000, 59, 931-945.	0.9	265
334	Method to correlate 1H MRSI and 18FDG-PET. <i>Magnetic Resonance in Medicine</i> , 2000, 43, 244-250.	1.9	42
335	Effects of Subcortical Cerebral Infarction on Cortical Glucose Metabolism and Cognitive Function. <i>Archives of Neurology</i> , 1999, 56, 809.	4.9	94
336	Brain perfusion imaging predicts survival in Alzheimer's disease. <i>Neurology</i> , 1998, 51, 1009-1013.	1.5	40
337	Clinical Studies of Cerebral Blood Flow in Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 1997, 826, 254-262.	1.8	82
338	SPECT Perfusion Imaging in the Diagnosis of Dementia. <i>Journal of Neuroimaging</i> , 1995, 5, S45-52.	1.0	19
339	Imaging Studies of Aging, Neurodegenerative Disease, and Alcoholism. <i>Alcohol Health and Research World</i> , 1995, 19, 279-286.	0.2	1
340	Anosognosia in Alzheimer's disease: Relationships to depression, cognitive function, and cerebral perfusion. <i>Neuropsychology, Development and Cognition Section A: Journal of Clinical and Experimental Neuropsychology</i> , 1993, 15, 231-244.	1.4	258
341	Speed of memory scanning is not affected in early HIV-1 infection. <i>Neuropsychology, Development and Cognition Section A: Journal of Clinical and Experimental Neuropsychology</i> , 1993, 15, 311-320.	1.4	32
342	Single-Photon Emission Computed Tomographic Perfusion Imaging in Autopsy-Diagnosed Dementia. <i>Journal of Neuroimaging</i> , 1993, 3, 93-99.	1.0	9

#	ARTICLE	IF	CITATIONS
343	Performance of patients with early HIV-1 infection on the stroop task. Neuropsychology, Development and Cognition Section A: Journal of Clinical and Experimental Neuropsychology, 1992, 14, 857-868.	1.4	78
344	Single-Photon Emission Computed Tomography Studies of Regional Cerebral Blood Flow in Multiple Infarct Dementia. Journal of Neuroimaging, 1992, 2, 79-85.	1.0	11
345	Reduced temporal lobe blood flow in alzheimer's disease. Neurobiology of Aging, 1992, 13, 483-491.	1.5	89
346	Visuoconstructive performance and regional cerebral glucose metabolism in alzheimer's disease. Neuropsychology, Development and Cognition Section A: Journal of Clinical and Experimental Neuropsychology, 1991, 13, 752-772.	1.4	64
347	Mental Status as a Predictor of Daily Function in Progressive Dementia. Gerontologist, The, 1989, 29, 804-807.	2.3	106
348	Altered excitatory and inhibitory neuronal subpopulation parameters are distinctly associated with tau and amyloid in Alzheimer's disease. ELife, 0, 11, .	2.8	45